HOOKIPA Pharma
HOOK
HOOK was delisted on the 7th of August, 2025.
54 hedge funds and large institutions have $38.3M invested in HOOKIPA Pharma in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 10 closing their positions.
0.25% less ownership
Funds ownership: 5.79% → 5.54% (-0.25%)
7% less funds holding
Funds holding: 58 → 54 (-4)
20% less capital invested
Capital invested by funds: $48M → $38.3M (-$9.69M)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
30% less call options, than puts
Call options by funds: $72K | Put options by funds: $103K
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$190K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$172K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$113K |
| 4 |
Renaissance Technologies
New York
|
+$72.9K |
| 5 |
Two Sigma Investments
New York
|
+$58.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$980K |
| 2 |
Millennium Management
New York
|
-$492K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$207K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$149K |
| 5 |
Morgan Stanley
New York
|
-$95.8K |
HOOK Hedge Fund Activity: Q3 2022 in Review
54 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in HOOKIPA Pharma (HOOK) for Q3 2022, worth a combined $38.3M — down 20% from $48M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of HOOK and 6 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 11 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $190K. The largest seller was Fidelity Investments, cutting an estimated $980K.
- 54 institutional investors held HOOKIPA Pharma (HOOK) as of Q3 2022, down from 58 in Q2 2022.
- Funds reported $38.3M of HOOKIPA Pharma stock for Q3 2022, down 20% quarter-over-quarter.
- 6 funds opened new HOOKIPA Pharma positions in Q3 2022 and 10 closed out, a net change of -4 holders.
- The largest HOOKIPA Pharma buyer in Q3 2022 was Bridgeway Capital Management, an estimated $190K added.
- The largest HOOKIPA Pharma seller in Q3 2022 was Fidelity Investments, an estimated $980K sold.
Based on aggregated 13F filings for Q3 2022.